Filtered By:
Specialty: Drugs & Pharmacology
Drug: Cilostazol
This page shows you your search results in order of date.
Order by Relevance | Date
Total 18 results found since Jan 2013.
Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke
ConclusionsThis real-world study suggests that cilostazol is effective and safe for noncardioembolic ischemic stroke and may be associated with better effectiveness in hypertensive patients compared to clopidogrel.
Source: European Journal of Clinical Pharmacology - June 13, 2023 Category: Drugs & Pharmacology Source Type: research
Antiplatelet therapy for secondary prevention of lacunar stroke: a systematic review and network meta-analysis
ConclusionsThis meta-analysis suggests that cilostazol may be a priority option for secondary prevention of patients with LS. These findings still need further study in the future.
Source: European Journal of Clinical Pharmacology - November 7, 2022 Category: Drugs & Pharmacology Source Type: research
Antiplatelet Use in Ischemic Stroke
CONCLUSIONS: Although good evidence exists for the use of certain antiplatelet agents postischemic stroke, there are considerable opportunities for future research to investigate personalized therapies. These include screening patients for platelet polymorphisms that confer antiplatelet resistance and for randomized trials including more racially diverse populations.PMID:35094598 | DOI:10.1177/10600280211073009
Source: The Annals of Pharmacotherapy - January 31, 2022 Category: Drugs & Pharmacology Authors: Marharyta Kamarova Sheharyar Baig Hamish Patel Kimberley Monks Mohammed Wasay Ali Ali Jessica Redgrave Arshad Majid Simon M Bell Source Type: research
Update on Cilostazol: A Critical Review of its Antithrombotic and Cardiovascular Actions and its Clinical Applications
This article is protected by copyright. All rights reserved.PMID:34671983 | DOI:10.1002/jcph.1988
Source: The Journal of Clinical Pharmacology - October 21, 2021 Category: Drugs & Pharmacology Authors: Antonis A Manolis Theodora A Manolis Helen Melita Dimitri P Mikhailidis Antonis S Manolis Source Type: research
The use of cilostazol for secondary stroke prevention: isn't time to be evaluated in Western countries?
Authors: Di Napoli M, Singh P, Lattanzi S, Divani AD
PMID: 31935129 [PubMed - as supplied by publisher]
Source: Expert Opinion on Pharmacotherapy - January 16, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Cilostazol for treatment of cerebral infarction.
Authors: Noma K, Higashi Y
Abstract
INTRODUCTION: Stroke not only causes critical disability and death but is also a cause of anxiety with the possibility of secondary cardiovascular events including secondary ischemic stroke. Indeed, patients with a history of previous stroke have a high rate of stroke recurrence, indicating the clinical importance of secondary stroke prevention. Area of covered: This review provides an overview of the pooled evidence for cilostazol's use in the management of secondary stroke prevention. Among the various antiplatelet agents that are available, aspirin is the most frequently used ...
Source: Expert Opinion on Pharmacotherapy - September 14, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
CONCLUSIONS: In patients with CAD, adverse clinical outcomes were not significantly different when DDC was compared to the other antiplatelet regimens. In addition, bleeding events were also similarly manifested when DDC was compared to DAPT, TAPT or ticagrelor/prasugrel.
PMID: 30176938 [PubMed - in process]
Source: BMC Pharmacology and Toxicology - September 5, 2018 Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation?
CONCLUSION: More potent antithrombotic regimens increase bleeding and should only be considered on an individual basis, after careful risk stratification. Accurate risk stratification of ACS patients, for both ischaemic and bleeding risk, is essential to allow individualised treatment.
PMID: 29345587 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - January 16, 2018 Category: Drugs & Pharmacology Authors: Spinthakis N, Farag M, Akhtar Z, Gorog DA Tags: Curr Vasc Pharmacol Source Type: research
Effects of cilostazol and renin-angiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study
Conclusion Treatment with cilostazol plus ACEI or ARB was observed to prevent worsening of renal progression in patients in the stages 1 –2.
Source: International Journal of Clinical Pharmacy - December 27, 2017 Category: Drugs & Pharmacology Source Type: research
